Symptoms of Autoimmune Hepatitis Flare-Up
In patients with autoimmune hepatitis who have difficulty tapering corticosteroids, a disease flare-up typically manifests with elevated liver transaminases (AST/ALT), rising bilirubin, and recurrent symptoms of fatigue, jaundice, and right upper quadrant discomfort. 1
Biochemical Indicators of Flare
- Elevated transaminases (AST/ALT) are the primary laboratory marker of disease reactivation, often rising to >3 times the upper limit of normal during a flare 1
- Hyperbilirubinemia may develop, particularly in severe flares, with total bilirubin rising above baseline levels 1, 2
- Elevated alkaline phosphatase and gamma-glutamyl transferase may accompany the transaminase elevation 1
- Rising inflammatory markers including elevated erythrocyte sedimentation rate or C-reactive protein can indicate active inflammation 1
Clinical Symptoms
- Fatigue and malaise are among the most common presenting symptoms of disease reactivation 1, 2
- Jaundice (yellowing of skin and sclera) develops when bilirubin becomes significantly elevated 1, 2
- Right upper quadrant abdominal discomfort or pain may occur with hepatic inflammation 1
- Nausea, anorexia, and weight loss can accompany more severe flares 1
- Dark urine and pale stools reflect cholestatic features when present 1
Timing and Context
- Flares most commonly occur during corticosteroid tapering, particularly when prednisone is reduced below 10-20 mg daily 1, 3
- Relapse after drug withdrawal occurs in 50-79% of patients, typically within 6 months of discontinuation 4
- Flares can develop within 3 months of stopping corticosteroid therapy in steroid-dependent patients 1
Histological Features (When Biopsy Performed)
- Interface hepatitis with lymphoplasmacytic infiltration is the hallmark finding 1, 2
- Lobular inflammation with hepatocyte necrosis may be present 2
- Plasma cell infiltration is characteristic of autoimmune hepatitis activity 1
Critical Pitfalls to Avoid
- Do not attribute symptoms solely to corticosteroid withdrawal syndrome (myalgia, arthralgia, malaise) without checking liver biochemistries, as true disease flare requires different management 5
- Rule out competing causes of elevated transaminases including viral hepatitis reactivation (particularly hepatitis B), drug-induced liver injury, or superimposed infections before attributing symptoms to autoimmune hepatitis flare 5
- Monitor for adrenal insufficiency symptoms (hypotension, hyponatremia, hypoglycemia) which can occur concurrently with disease flare during rapid steroid taper 5
Monitoring Strategy During Taper
- Check liver biochemistries (AST, ALT, bilirubin, alkaline phosphatase) every 1-2 weeks during active tapering to detect early biochemical relapse 1, 3
- Slow or halt the taper if transaminases rise above 2 times baseline or if any clinical symptoms develop 1, 3
- Consider liver biopsy if biochemical abnormalities persist despite treatment adjustment to confirm active inflammation versus other causes 1